Uniunea Europeană - franceză - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infections des voies respiratoires - les antibactériens à usage systémique, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

viatris limited - bésilate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Élévation du segment st infarctus aigu du myocarde, en association avec de l'aas dans traitée médicalement les patients éligibles à un traitement thrombolytique. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pour de plus amples informations, veuillez vous reporter à la section 5.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

taw pharma (ireland) limited - chlorhydrate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agents antithrombotiques - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Canada - franceză - Health Canada

steris corporation - o-phénylphénol; clorophène; p-tert-pentylphénol - liquide - 10%; 8.5%; 2% - o-phénylphénol 10%; clorophène 8.5%; p-tert-pentylphénol 2% - disinfectants (for agents used on object)

Belgia - franceză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - oxalate d'escitalopram 63,875 mg - eq. escitalopram 5 mg - comprimé orodispersible - 5 mg - oxalate d'escitalopram 63.875 mg - escitalopram

Belgia - franceză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - oxalate d'escitalopram 12,775 mg - eq. escitalopram 10 mg - comprimé orodispersible - 10 mg - oxalate d'escitalopram 12.775 mg - escitalopram

Belgia - franceză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - oxalate d'escitalopram 25,55 mg - eq. escitalopram 20 mg - comprimé orodispersible - 20 mg - oxalate d'escitalopram 25.55 mg - escitalopram

Belgia - franceză - Adama

adama - emulsion concentrée (ec) - bupirimate - fongicide